October 13, 2025
 
 
RedChip Logo
Small Stocks, Big Money™
Weekly Newsletter
REDCHIP.COM
 
Feature News
 
Nova Minerals Secures Prime Site for U.S. Antimony Refinery, Targets Military-Grade Production in 2026
 
Nova Minerals (Nasdaq: NVA) has secured a 42.81-acre industrial site at Alaska’s Port MacKenzie for its proposed antimony refinery, a critical step toward establishing the first fully integrated U.S. supply chain for military-spec antimony. Backed by a $43.4M award from the U.S. Department of War and strong state support, Nova is fast-tracking Phase 1 production, with first deliveries targeted within 24 months, positioning the company as a key player in national defense and industrial supply chains.
 
 
 
 
 
 
 
 
 
Nexalin’s Gen-2 SYNC Device Shows Breakthrough Alzheimer’s Results in Peer-Reviewed Study
 
Nexalin Technology (Nasdaq: NXL) published compelling clinical results in Radiology showing its 40-Hz Gen-2 SYNC DIFS™ neurostimulation device significantly improves cognitive function and brain connectivity in mild Alzheimer’s patients, without drugs or side effects. The sham-controlled study validates the device’s mechanism via fMRI and strengthens Nexalin’s global strategy to capture a share of the $20B Alzheimer’s market with its non-invasive, deep-brain neurostimulation technology.
 
 
 
 
 
 
 
New Era Advances Flagship AI Data Center to Phase Two Engineering, Strengthens Balance Sheet
 
New Era Energy & Digital (Nasdaq: NUAI) kicked off Phase Two engineering for its West Texas-based Texas Critical Data Center (TCDC), a joint venture targeting scalable AI and GPU infrastructure with plans to exceed 1 GW capacity. With land holdings expanding to 438 acres and streamlined air permitting underway, the project is on track for 2026 construction. A recent 8-K filing also revealed the retirement of convertible notes and improved financial flexibility, reinforcing New Era’s disciplined execution and long-term vision in next-gen digital infrastructure.
 
 
 
 
 
 
 
 
 
Bimergen Secures $200M Equity Commitment to Accelerate 2 GW Battery Storage Pipeline
 
Bimergen Energy (OTCQB: BESS) landed a transformative equity commitment of up to $200 million from a leading European energy firm to fund its utility-scale battery energy storage projects across the U.S. An previously announced initial $10 million will jumpstart early-stage development, supporting Bimergen’s rapidly advancing 2 GW project pipeline and reinforcing its position in the high-growth grid resilience and energy storage market.
 
 
 
 
 
 
 
NioCorp Secures Final Land for Elk Creek Critical Minerals Project, Clearing Path to Construction
 
NioCorp Developments (Nasdaq: NB) has acquired the final 325.77 acres needed to fully control the Elk Creek Project site in Nebraska, securing all surface and mineral rights required to begin construction upon project financing. With a 38-year mine life and future expansion potential, Elk Creek is positioned to become a major U.S. source of niobium, scandium, titanium, and rare earths vital to defense, clean energy, and high-performance manufacturing.
 
 
 
 
 
Recent News
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RedChip TV
 
 
 
 
RedChip Highlights Lantern Pharma Inc. (NASDAQ: LTRN) & Enlivex Therapeutics Ltd. (NASDAQ: ENLV)
 
 
 
 
 
 
 
RedChat Ad
 
 
Unlock Smarter Investing with RedChat
RedChat Ad
Tired of sifting through endless filings? Let RedChat do the heavy lifting. Get real-time, data-driven insights on over 2,000 small-cap stocks—instantly. Save time, make informed decisions, and stay ahead of the market.
Access RedChat now, free of charge.
START USING REDCHAT
 
Recent Research Coverage Updates
 
Company Rating Price Target Firm Report Date
Alliance Entertainment (Nasdaq: AENT) Buy $11 Noble Capital October 6, 2025
FibroBiologics (Nasdaq: FBLG) Buy $4 Maxim September 22, 2025
XORTX Therapeutics (Nasdaq: XRTX) Buy $14 AGP September 18, 2025
FibroBiologics (Nasdaq: FBLG) Buy $10 H.C. Wainwright September 12, 2025
Alliance Entertainment (Nasdaq: AENT) Buy $10 Maxim September 11, 2025
FibroBiologics (Nasdaq: FBLG) Buy $16 D Boral September 10, 2025
Greenwich LifeSciences (Nasdaq: GLSI) Buy $45 Noble August 20, 2025
Nexalin Technology (Nasdaq: NXL) Buy $4 Maxim August 19, 2025
Atossa Therapeutics (Nasdaq: ATOS) Buy $7 HC Waingwright August 12, 2025
Atossa Therapeutics (Nasdaq: ATOS) Buy $4 Maxim August 12, 2025
Atossa Therapeutics (Nasdaq: ATOS) Buy $4 Maxim August 12, 2025
FibroBiologics (Nasdaq: FBLG) Buy $16 D Boral July 29, 2025
Connect Biopharma (Nasdaq: CNTB) Buy $7.5 Northland Securities July 23, 2025
Connect Biopharma (Nasdaq: CNTB) Buy $4 Titan Partners July 17, 2025
NioCorp (Nasdaq: NB) Buy $5 Maxim July 10, 2025
Connect Biopharma (Nasdaq: CNTB) Buy $7 H.C. Wainwright July 9, 2025
FibroBiologics (Nasdaq: FBLG) Buy $16 D Boral July 9, 2025
NioCorp (Nasdaq: NB) Buy $4 HC Wainwright July 2, 2025
Alliance Entertainment (Nasdaq: AENT) Buy $10 Maxim July 1, 2025
 
 
 
Podcast Logo
Small Stocks, Big Money™ Podcast
The podcast features in-depth interviews with CEO's from the top names in small-cap stocks, providing listeners with a unique perspective not found anywhere else.
Available on:
Amazon Music Apple Podcasts Spotify
LEARN MORE
 
 
Upcoming Events
 
 
15
 
 
OCT 2025
 
FatPipe (NASDAQ: FATN)
4:15pm Eastern
 
FatPipe, Inc. (Nasdaq: FATN) is a pioneer in secure, software-defined networking technologies that simplify and fortify enterprise connectivity.
 
 
 
 
 
 
 
16
 
 
OCT 2025
 
Jackpot Digital (OTCQB: JPOTF)
4:15pm Eastern
 
Jackpot Digital Inc. is the leading provider of electronic poker table games, offering innovative gaming solutions to casinos worldwide.
 
 
 
 
 
 
 
22
 
 
OCT 2025
 
60 Degrees Pharmaceuticals (NASDAQ: SXTP)
04:15pm Eastern
 
60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases.
 
 
 
 
 
 
 
Archived Events
 
 
8
 
 
OCT 2025
 
BioVie (NASDAQ: BIVI)
4:15pm Eastern
 
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson’s disease and long COVID) and advanced liver disease.
 
 
 
 
 
 
Quote of the Week
 
"How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case."
— Robert G. Allen
 
 
Order "Small Stocks, Big Money™ Today!
 
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
 
 
 
 
 
 
 
Lesson of the Week
 
Buying is only half the equation. You also need to know when to sell.